Wegovy weight loss before and after: what the results really look like

The biggest misconception: dramatic 'before and after' photos are not the typical story

Search for weight loss with Wegovy before and after and you will find extraordinary images, sixty-pound transformations in six months, sometimes less. Those cases exist, but they sit at the far end of the distribution, not the middle of it. The STEP 1 trial, published in the New England Journal of Medicine, randomised 1,961 adults with obesity or overweight alongside a weight-related condition. Over 68 weeks, participants using semaglutide 2.4mg lost an average of around 15% of body weight. That is substantial, for someone starting at 100kg, roughly 15kg. But it is also an average, which means half the participants lost less.

If you want a grounded sense of what real people's journeys look like, our Wegovy before and after page sets out a range of outcomes drawn from trial data and clinical experience, rather than the exceptional cases that tend to circulate online. Knowing that before you start matters, because unrealistic expectations are one of the commonest reasons people feel Wegovy has 'failed' them when it has actually been working.

One quick check worth doing: if you are tracking your progress, weigh yourself on the same scales at the same time of day each week rather than each morning. Daily fluctuations of 1–2kg from hydration and food volume are completely normal and can obscure a real downward trend that only becomes visible week-on-week.

Our guide to Wegovy results before and after goes deeper on what the trial data actually measured and how those figures were reported.

How weight loss with Wegovy typically unfolds across the treatment period

The first four weeks are rarely dramatic. Semaglutide starts at 0.25mg, a tolerability dose whose job is to let your system adjust, not to produce noticeable weight loss. Dose increases happen roughly every four weeks, guided by your prescriber, moving through 0.5mg, 1mg and 1.7mg before reaching the 2.4mg maintenance dose. For many people, appetite suppression becomes meaningfully noticeable somewhere around the 1mg to 1.7mg stage. Weight change before that point can feel frustratingly slow.

The steepest rate of loss in the STEP 1 trial occurred roughly between weeks 12 and 40. After that, the curve flattens as the body adapts. This is not a failure of the medicine; it is a well-documented physiological response. People who plateau sometimes assume they need a higher dose or a different treatment, when patience and consistency with lifestyle habits often restore momentum. Our page on how long before weight loss on Wegovy explains the timeline in more detail, including when most people report noticing a genuine difference.

For the people who stayed on 7.2mg (the higher maintenance dose approved by the MHRA in early 2026) early trial data suggested average losses of around 20.7% over 72 weeks. That narrows the gap considerably with other treatment options, though your prescriber would discuss whether the higher dose is appropriate for your circumstances.

Why 'after' is as important as the weight figure itself

Clinical before-and-after data does not stop at the weight number. The STEP 1 trial also measured waist circumference, blood pressure, blood sugar markers and quality-of-life scores. Many participants saw improvements across several of those measures, sometimes independently of how much weight they lost. That context matters, because it reframes what a 'result' actually means.

It also matters because of what happens when treatment ends. A large follow-up study found that most of the weight lost during the trial returned within about a year of stopping semaglutide, roughly two-thirds of it, on average. This does not make Wegovy ineffective; it reflects that obesity is a chronic condition with ongoing biological drivers. Wegovy addresses those drivers while you are taking it. The implications of long-term use are something worth discussing openly with your prescriber, alongside how it fits your wider health picture. You can find more context on the Wegovy treatment overview page.

Cost is a practical part of that longer-term picture. Comparing Wegovy prices in the UK is worth doing carefully, because headline prices do not always include prescriptions, clinical reviews or aftercare.

What shapes individual results, and why two people on the same dose look different

Genetics, starting metabolic rate, gut microbiome composition and the presence of conditions like insulin resistance all influence how someone responds to semaglutide. So does the lifestyle context: trial participants received dietary counselling and activity guidance alongside the medicine. The 15% average figure comes from that supported setting, not from taking the pen alone.

Dose also matters. Participants who could not tolerate titration to 2.4mg lost less weight on average than those who reached and stayed at the full maintenance dose. Nausea, the most commonly reported side effect, peaks after dose increases and usually settles within a few days to two weeks, per NHS guidance on semaglutide. Slowing the titration schedule, under prescriber guidance, can help people stay on treatment long enough for results to accumulate. If you are curious about very early outcomes, there is specific information on what six weeks on Wegovy looks like for most people.

None of this is a reason for pessimism. It is a reason to go in with accurate expectations, and with a prescriber who is genuinely available to adjust the plan. If you would like to discuss whether Wegovy is clinically appropriate for you, our prescribers are here.